Hypereosinophilic Syndrome
Cross-source consensus on Hypereosinophilic Syndrome from 1 sources and 67 claims.
1 sources · 67 claims
Uses
How it works
Dosage & preparation
Background
Evidence quality
Highlighted claims
- Benralizumab was evaluated as a treatment for hypereosinophilic syndrome in a phase 3 randomized controlled trial. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- Prior use of HES-related biologic therapy within the preceding 12 months was tracked as a baseline characteristic of trial participants. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- The total trial population for the benralizumab HES study consisted of 133 participants. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- Some patients in the HES trial had received prior HES-related biologic therapy within the preceding 12 months. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- The HES trial enrolled 133 total participants, with 67 assigned to the benralizumab group. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- The total trial population for the benralizumab HES study comprised 133 participants. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- Hypereosinophilic syndrome is the indication for which benralizumab was evaluated in this phase 3 trial. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- The trial enrolled 133 participants in total, with 67 assigned to the benralizumab treatment group. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- The full HES trial enrolled 133 patients across all treatment arms. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems
- Prior HES-related biologic therapy within the preceding 12 months was tracked as a baseline patient characteristic. — Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems